A maturity model for clinical trial design
Harnessing the Power of Modeling and Simulation Since 2000 there has been growing concern in the pharmaceutical industry over the escalating cost of drug development and lack of a corresponding...
View ArticleLilly’s approach to the clinical trial paradox
There was an excellent interview with Eli Lilly’s Chief Medical Officer, Timothy Garnett, in the February issue of Life Science Leader, that I’ve been meaning to write about for a while and a weekend...
View ArticlePatient sub-population effects: The regulator’s dilemma
At the DIA/FDA statistics workshop last week, amongst the many and varied interesting presentations, the one that most caught my eye was Dr Armin Koch’s talk on examples of patient sub-populations. (Dr...
View ArticleReport on the current state of play in the adoption of adaptive trials...
There’s a really good article in Applied Clinical Trials on the state of play in the industry of the use of adaptive clinical trials by Ken Getz of Tufts, click here for full article reports that in...
View ArticleAdaptive trials for small to medium sized biotechs and pharmaceutical companies
I’ve spoken to a few people in smaller biotechs and pharmaceuticals recently, and it’s clear that, though there are opportunities and appetites amongst these companies to use adaptive trials, there is...
View ArticleHow should we test potential treatments for Ebola?
A pressing problem and a very modern dilemma, how should we test potential treatments for Ebola? We know that a double-blind randomised clinical trial (RCT) is the gold standard for generating evidence...
View ArticleAn adaptive trial should be like a driverless car – boring and predictable
On the BBC world service in 2013 there was an account by two technology journalists of going for a ride in the Google “Driverless Car”. They recounted their emotional journey as the Google engineer in...
View ArticleMisbehaving – what can behavioural economics tell us about the slow uptake of...
I had a profound insight the other day into (possibly) the true nature of the problem of the slow adoption of adaptive trials. Listening to one of my favourite podcasts – “Peter Day’s World of...
View Article
More Pages to Explore .....